Methodologic diligence is needed to define and validate tumor-size response metrics to predict overall survival in first-line metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 31, Issue 34, 2013, Pages 4373-7374

  Mansmann, Ulrich R ^a   Laubender, Rüdiger P ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST METASTASIS; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LETTER; MEASUREMENT ERROR; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; TUMOR GROWTH; TUMOR VOLUME; COLORECTAL TUMOR; FEMALE; MALE; NOTE; PATHOLOGY; COLORECTAL NEOPLASMS;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE;

EID: 84892858817     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.2954     Document Type: Letter

References (6)

1. Claret L, Gupta M, Han K, et al: Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. J Clin Oncol 31:2110-2114, 2013
2. Claret L, Girard P, Hoff PM, et al: Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 27:4103-4108, 2009
3. Ibrahim JG, Chu H, Chen LM: Basic concepts and methods for joint models of longitudinal and survival data. J Clin Oncol 28:2796-2801, 2010
4. Rochon J: Supplementing the intent-to-treat analysis: Accounting for covariates observed postrandomization in clinical trials. JASA 90:292-300, 1995
5. Burzykowski T, Molenberghs G, BuyseM(eds): The Evaluation of Surrogate Endpoints. New York, NY, Springer, 2005
6. Maitland ML, Schwartz LH, Ratain MJ: Time to tumor growth: A model end point and new metric system for oncology clinical trials. J Clin Oncol 31:2070-2072, 2013